Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00299130 · OUTCOME

Percent Change From Baseline in Physician's Global Assessment of Disease Activity

A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis · Source last updated 2017-04-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
percent change
Interval / dispersion
Standard Deviation
Time frame
Baseline, Week 24 and Week 48

What was measured

The physician's assessment of the participant's current disease activity on a 100 mm horizontal VAS, where the left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme (100 mm) as "maximum disease activity". The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.

Analysis population: Intent-to-treat population, LOCF was used. "N" indicates the number of participants with non-missing data at each time point.

Groups in this outcome

Placebo + MTX

Participants received placebo intravenous infusion on Days 1 and 15. From Week 16 onwards, participants could switch to receive rituximab 0.5 g (on Days 1 and 15) every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Placebo and rituximab infusions were preceded with 100 mg intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of MTX and ≥ 5 mg/week folic acid for the duration of their participation in the study. All participants entered a 48-week safety follow-up (SFU) period following the treatment period.

Rituximab 2 x 0.5 g + MTX

Participants received 0.5 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study. All participants entered a 48-week safety follow-up (SFU) period following the treatment period.

Rituximab 2 x 1.0 g + MTX

Participants received 1.0 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study. All participants entered a 48-week safety follow-up (SFU) period following the treatment period.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Placebo + MTX172
Rituximab 2 x 0.5 g + MTX167
Rituximab 2 x 1.0 g + MTX170

Reported measurements

Week 24 [N=172, 166, 170]
Values in percent change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Placebo + MTX-25.338.52Not reportedNot reportedNot reported
Rituximab 2 x 0.5 g + MTX-36.961.26Not reportedNot reportedNot reported
Rituximab 2 x 1.0 g + MTX-35.446.99Not reportedNot reportedNot reported
Week 48 [N=172, 166, 170]
Values in percent change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Placebo + MTX-39.439.95Not reportedNot reportedNot reported
Rituximab 2 x 0.5 g + MTX-40.574.54Not reportedNot reportedNot reported
Rituximab 2 x 1.0 g + MTX-49.040.01Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        38.52
        value
        -25.3
      2. group Id
        OG001
        spread
        61.26
        value
        -36.9
      3. group Id
        OG002
        spread
        46.99
        value
        -35.4
    title
    Week 24 [N=172, 166, 170]
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        39.95
        value
        -39.4
      2. group Id
        OG001
        spread
        74.54
        value
        -40.5
      3. group Id
        OG002
        spread
        40.01
        value
        -49.0
    title
    Week 48 [N=172, 166, 170]
denoms
  1. counts
    1. group Id
      OG000
      value
      172
    2. group Id
      OG001
      value
      167
    3. group Id
      OG002
      value
      170
    units
    Participants
description
The physician's assessment of the participant's current disease activity on a 100 mm horizontal VAS, where the left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme (100 mm) as "maximum disease activity". The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.
dispersion Type
Standard Deviation
groups
  1. description
    Participants received placebo intravenous infusion on Days 1 and 15. From Week 16 onwards, participants could switch to receive rituximab 0.5 g (on Days 1 and 15) every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Placebo and rituximab infusions were preceded with 100 mg intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of MTX and ≥ 5 mg/week folic acid for the duration of their participation in the study. All participants entered a 48-week safety follow-up (SFU) period following the treatment period.
    id
    OG000
    title
    Placebo + MTX
  2. description
    Participants received 0.5 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study. All participants entered a 48-week safety follow-up (SFU) period following the treatment period.
    id
    OG001
    title
    Rituximab 2 x 0.5 g + MTX
  3. description
    Participants received 1.0 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study. All participants entered a 48-week safety follow-up (SFU) period following the treatment period.
    id
    OG002
    title
    Rituximab 2 x 1.0 g + MTX
param Type
MEAN
population Description
Intent-to-treat population, LOCF was used. "N" indicates the number of participants with non-missing data at each time point.
reporting Status
POSTED
time Frame
Baseline, Week 24 and Week 48
title
Percent Change From Baseline in Physician's Global Assessment of Disease Activity
type
SECONDARY
unit Of Measure
percent change

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice